Dipaxin—2-Diphenylacetyl-1,3-Indandione; Clinical Evaluation of a New Anticoagulant
In the course of development of new anticoagulants, an indandione derivative has been subjected to a clinical evaluation. The new agent is one of the most potent hypoprothrombinemic substance known but it is readily counteracted with vitamin K. The agent was administered to a large series of patients with thromboembolic diseases and control of anticoagulant therapy was observed to be simple, reproducible, with a good predictability of response as well as with absence of toxic phenomena and a low order of bleeding complications. It has been administered to 11 patients for ambulant anticoagulant care for periods up to 18 months with satisfactory results and it appears to be especially suitable for long-term maintenance therapy.
- © 1955 American Heart Association, Inc.